Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 and KN046 in HER2-positive Solid Tumors
NCT04521179Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab, erfonrilimab in HER2-positive solid tumor, sponsored by Alphamab Oncology. Started Dec 2020; status: completed.
02
Drugs
anbenitamaberfonrilimab
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT04521179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521179.